Response to Osimertinib in a Patient with Non-Small Cell Lung Cancer and Two Uncommon *EGFR* Mutations by Christoforos Astaras, Adrienne Bettini, Daniel C. Betticher

Get full text

Outcomes in Patients With Resectable Stage III NSCLC Who Did Not Have Definitive Surgery After Neoadjuvant Treatment—A Retrospective Analysis of the SAKK Trials 16/96, 16/00, 16/01... by Sabine Raimann, MD, Sämi Schär, PhD, Stefanie Hayoz, PhD, Matthias Guckenberger, MD, Tobias Finazzi, MD, PhD, Isabelle Opitz, MD, Sabine Schmid, MD, Michael Mark, MD, Alfredo Addeo, MD, Laetitia A. Mauti, MD, PhD, Daniel C. Betticher, MD, Hans-Beat Ris, MD, Roger Stupp, MD, Alessandra Curioni-Fontecedro, MD, Solange Peters, MD, PhD, Martin Früh, MD, Sacha I. Rothschild, MD, PhD, Miklos Pless, MD, David König, MD

Get full text